Glenmark Pharmaceuticals Ltd. - Product Pipeline Review - 2016

  • ID: 3832302
  • Company Profile
  • 46 pages
  • Global Markets Direct
1 of 4
Glenmark Pharmaceuticals Ltd. - Product Pipeline Review - 2016

Summary

‘Glenmark Pharmaceuticals Ltd. - Product Pipeline Review - 2016’, provides an overview of the Glenmark Pharmaceuticals Ltd.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Glenmark Pharmaceuticals Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Glenmark Pharmaceuticals Ltd.
- The report provides overview of Glenmark Pharmaceuticals Ltd. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Glenmark Pharmaceuticals Ltd.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Glenmark Pharmaceuticals Ltd.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Glenmark Pharmaceuticals Ltd.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Glenmark Pharmaceuticals Ltd.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glenmark Pharmaceuticals Ltd.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Glenmark Pharmaceuticals Ltd. Snapshot

Glenmark Pharmaceuticals Ltd. Overview

Key Information

Key Facts

Glenmark Pharmaceuticals Ltd. - Research and Development Overview

Key Therapeutic Areas

Glenmark Pharmaceuticals Ltd. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Glenmark Pharmaceuticals Ltd. - Pipeline Products Glance

Glenmark Pharmaceuticals Ltd. - Late Stage Pipeline Products

Phase III Products/Combination Treatment Modalities

Glenmark Pharmaceuticals Ltd. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Glenmark Pharmaceuticals Ltd. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Glenmark Pharmaceuticals Ltd. - Drug Profiles

crofelemer DR

Product Description

Mechanism of Action

R&D Progress

GSP-301

Product Description

Mechanism of Action

R&D Progress

GBR-830

Product Description

Mechanism of Action

R&D Progress

GRC-17536

Product Description

Mechanism of Action

R&D Progress

GBR-1302

Product Description

Mechanism of Action

R&D Progress

GBR-900

Product Description

Mechanism of Action

R&D Progress

GRC-27864

Product Description

Mechanism of Action

R&D Progress

GBR-1342

Product Description

Mechanism of Action

R&D Progress

GBR-600

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize TRPM8 for Neuropathic Pain

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit PDE10A for Schizophrenia and Psychosis

Product Description

Mechanism of Action

R&D Progress

Glenmark Pharmaceuticals Ltd. - Pipeline Analysis

Glenmark Pharmaceuticals Ltd. - Pipeline Products by Target

Glenmark Pharmaceuticals Ltd. - Pipeline Products by Route of Administration

Glenmark Pharmaceuticals Ltd. - Pipeline Products by Molecule Type

Glenmark Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action

Glenmark Pharmaceuticals Ltd. - Recent Pipeline Updates

Glenmark Pharmaceuticals Ltd. - Dormant Projects

Glenmark Pharmaceuticals Ltd. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

GRC-15300

GRC-6211

oglemilast

revamilast

Glenmark Pharmaceuticals Ltd. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 46List of Tables

Glenmark Pharmaceuticals Ltd., Key Information

Glenmark Pharmaceuticals Ltd., Key Facts

Glenmark Pharmaceuticals Ltd. - Pipeline by Indication, 2016

Glenmark Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2016

Glenmark Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2016

Glenmark Pharmaceuticals Ltd. - Partnered Products in Pipeline, 2016

Glenmark Pharmaceuticals Ltd. - Partnered Products/ Combination Treatment Modalities, 2016

Glenmark Pharmaceuticals Ltd. - Phase III, 2016

Glenmark Pharmaceuticals Ltd. - Phase II, 2016

Glenmark Pharmaceuticals Ltd. - Phase I, 2016

Glenmark Pharmaceuticals Ltd. - Preclinical, 2016

Glenmark Pharmaceuticals Ltd. - Pipeline by Target, 2016

Glenmark Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2016

Glenmark Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2016

Glenmark Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action, 2016

Glenmark Pharmaceuticals Ltd. - Recent Pipeline Updates, 2016

Glenmark Pharmaceuticals Ltd. - Dormant Developmental Projects,2016

Glenmark Pharmaceuticals Ltd. - Discontinued Pipeline Products, 2016

Glenmark Pharmaceuticals Ltd., Subsidiaries 42List of Figures

Glenmark Pharmaceuticals Ltd. - Pipeline by Top 10 Indication, 2016

Glenmark Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2016

Glenmark Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2016

Glenmark Pharmaceuticals Ltd. - Partnered Products in Pipeline, 2016

Glenmark Pharmaceuticals Ltd. - Pipeline by Top 10 Target, 2016

Glenmark Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2016

Glenmark Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2016

Glenmark Pharmaceuticals Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll